Latest filing published 28 Oct 2020 for Perspective Therapeutics, Inc., €13k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 17 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +45.2%Entry US$4.20 · Close at T+365 US$6.10
- -9.8%Entry US$4.10 · Close at T+365 US$3.70
- -19.2%Entry US$5.20 · Close at T+365 US$4.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Michael Krachon: trading record in brief
Michael Krachon appears in our data through filings on Perspective Therapeutics, Inc. shares, published by SEC (Form 4). We count 17 filings; the first trade dates from 20 November 2017 and the latest from 22 October 2020.
On the market, this insider has only ever bought: 17 purchases, €54k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 2020 to date brings 1 purchase and no sales.
In size, the median ticket on the buying side is €298. Of 17 purchases, 17 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Looking at 17 purchases old enough to measure, the stock rose over the following 90 days in 12% of cases; the median change was -17.3%. Past outcomes like these are no guarantee of what comes next.
On 28 October 2020 came the latest disclosure, an open-market purchase for €13k in Perspective Therapeutics, Inc. Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Michael Krachon
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 28,844 shares@ US$0.52100.0% of flowCommon StockSEC:0001437749-20-021859:0Canonical exit: 20 Jan 2021 (T+90)
- 50,000 shares@ US$0.389958.1% of flowCommon stockSEC:0001437749-19-023360:0Canonical exit: 18 Feb 2020 (T+90)
- 19,609 shares@ US$0.5015.6% of flowCommon StockSEC:0001437749-17-019679:0Canonical exit: 18 Feb 2018 (T+90)
- 6,965 shares@ US$0.505.5% of flowCommon StockSEC:0001437749-17-019679:1Canonical exit: 18 Feb 2018 (T+90)
- 10,600 shares@ US$0.508.4% of flowCommon StockSEC:0001437749-17-019679:2Canonical exit: 18 Feb 2018 (T+90)
- 700 shares@ US$0.500.6% of flowCommon StockSEC:0001437749-17-019679:3Canonical exit: 18 Feb 2018 (T+90)
- 1,400 shares@ US$0.501.1% of flowCommon StockSEC:0001437749-17-019679:4Canonical exit: 18 Feb 2018 (T+90)
- 126 shares@ US$0.470.1% of flowCommon StockSEC:0001437749-17-019679:5Canonical exit: 18 Feb 2018 (T+90)
- 500 shares@ US$0.470.4% of flowCommon StockSEC:0001437749-17-019679:6Canonical exit: 18 Feb 2018 (T+90)
- 200 shares@ US$0.460.1% of flowCommon StockSEC:0001437749-17-019679:7Canonical exit: 18 Feb 2018 (T+90)
- 10,160 shares@ US$0.508.1% of flowCommon StockSEC:0001437749-17-019679:8Canonical exit: 18 Feb 2018 (T+90)
- 300 shares@ US$0.470.2% of flowCommon StockSEC:0001437749-17-019679:9Canonical exit: 18 Feb 2018 (T+90)
- 40 shares@ US$0.490.0% of flowCommon StockSEC:0001437749-17-019679:10Canonical exit: 18 Feb 2018 (T+90)
- 200 shares@ US$0.480.2% of flowCommon StockSEC:0001437749-17-019679:11Canonical exit: 18 Feb 2018 (T+90)
- 200 shares@ US$0.470.1% of flowCommon StockSEC:0001437749-17-019679:12Canonical exit: 18 Feb 2018 (T+90)
- 100 shares@ US$0.480.1% of flowCommon StockSEC:0001437749-17-019679:13Canonical exit: 18 Feb 2018 (T+90)
- 3,900 shares@ US$0.483.0% of flowCommon StockSEC:0001437749-17-019679:14Canonical exit: 18 Feb 2018 (T+90)
17 of 17 declarations